{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T10:45:56Z","timestamp":1791888356630,"version":"4.3.4"},"reference-count":42,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T00:00:00Z","timestamp":1578355200000},"content-version":"vor","delay-in-days":1193,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Bayer Pharma AG"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1093\/annonc\/mdw282","type":"journal-article","created":{"date-parts":[[2016,9,26]],"date-time":"2016-09-26T07:27:31Z","timestamp":1474874851000},"page":"1928-1940","source":"Crossref","is-referenced-by-count":225,"title":["First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas"],"prefix":"10.1016","volume":"27","author":[{"given":"A.","family":"Patnaik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.J.","family":"Appleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.W.","family":"Tolcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.P.","family":"Papadopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Beeram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.W.","family":"Rasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.J.","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.C.","family":"Sachdev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Chadha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Fulk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Ejadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.M.","family":"Mountz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.T.","family":"Lotze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.G.S.","family":"Toledo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Jeffers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Pe\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Reif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Genvresse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.K.","family":"Ramanathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdw282_bb0010","doi-asserted-by":"crossref","first-page":"5497","DOI":"10.1038\/onc.2008.245","article-title":"PI3K pathway alterations in cancer: variations on a theme","volume":"27","author":"Yuan","year":"2008","journal-title":"Oncogene"},{"key":"10.1093\/annonc\/mdw282_bb0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1158\/1535-7163.MCT-08-0801","article-title":"Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapy","volume":"8","author":"Ihle","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"10.1093\/annonc\/mdw282_bb0020","doi-asserted-by":"crossref","first-page":"7564","DOI":"10.1073\/pnas.0702507104","article-title":"Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity","volume":"104","author":"Saal","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1093\/annonc\/mdw282_bb0025","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/nrc3860","article-title":"PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting","volume":"15","author":"Thorpe","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"10.1093\/annonc\/mdw282_bb0030","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1182\/blood-2013-11-538546","article-title":"Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-\u03b4, as therapy for previously treated indolent non-Hodgkin lymphoma","volume":"123","author":"Flinn","year":"2014","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdw282_bb0035","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","article-title":"PI3K\u03b4 inhibition by idelalisib in patients with relapsed indolent lymphoma","volume":"370","author":"Gopal","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdw282_bb0040","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1200\/JCO.2011.36.1360","article-title":"Phase I, dose-escalation study of BKM120, an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors","volume":"30","author":"Bendell","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw282_bb0045","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1158\/1078-0432.CCR-14-3262","article-title":"Phase I trial of the pan-PI3K inhibitor pilaralisib (SAR245408\/XL147) in patients with chronic lymphocytic leukemia (CLL) or relapsed\/refractory lymphoma","volume":"21","author":"Brown","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdw282_bb0050","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1158\/1078-0432.CCR-14-0947","article-title":"First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors","volume":"21","author":"Sarker","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdw282_bb0055","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1158\/1078-0432.CCR-13-1777","article-title":"Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245408 (XL147), an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors","volume":"20","author":"Shapiro","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdw282_bb0060","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1158\/1078-0432.CCR-14-1306","article-title":"First-in-human study of PF-05212384 (PKI-587), a small-molecule, intravenous, dual inhibitor of PI3K and mTOR in patients with advanced cancer","volume":"21","author":"Shapiro","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdw282_bb0065","article-title":"A Phase 1 evaluation of duvelisib (IPI-145), a PI3K-\u03b4,\u03b3 inhibitor, in patients with relapsed\/refractory iNHL","volume":"124","author":"Flinn","year":"2014","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1093\/annonc\/mdw282_bb0070","article-title":"Duvelisib (IPI-145), a phosphoinositide-3-kinase-\u03b4,\u03b3 inhibitor, shows activity in patients with relapsed\/refractory T-cell lymphoma","volume":"124","author":"Horwitz","year":"2014","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1093\/annonc\/mdw282_bb0075","unstructured":"K Haike, E Stasik, M Soujon et al. Molecular mechanisms supporting inhibition of PI3K isoforms by copanlisib in blocking B-cell signaling and tumor cell growth in diffuse large B-cell lymphoma. Poster 48 presented at the 2014 1st American Society of Hematology Meeting on Lymphoma Biology, Colorado Springs, Colorado, USA, 10\u201313 August."},{"key":"10.1093\/annonc\/mdw282_bb0080","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1158\/1535-7163.MCT-12-0993-T","article-title":"BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110\u03b1 and p110\u03b4 activities in tumor cell lines and xenograft models","volume":"12","author":"Liu","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"10.1093\/annonc\/mdw282_bb0085","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1200\/JCO.2007.14.5482","article-title":"Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a Phase I tumor pharmacodynamic study in patients with advanced solid tumors","volume":"26","author":"Tabernero","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw282_bb0090","doi-asserted-by":"crossref","first-page":"4688","DOI":"10.1200\/JCO.2011.35.5263","article-title":"First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors","volume":"29","author":"Yap","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw282_bb0095","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1200\/JCO.2011.39.7356","article-title":"Management of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR pathway","volume":"30","author":"Busaidy","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw282_bb0100","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw282_bb0105","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.2146\/ajhp100020","article-title":"Mammalian target of rapamycin: biological function and target for novel anticancer agents","volume":"67","author":"Borders","year":"2010","journal-title":"Am J Health Syst Pharm"},{"key":"10.1093\/annonc\/mdw282_bb0110","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/nature04694","article-title":"Critical role for the p110\u03b1 phosphoinositide-3-OH kinase in growth and metabolic regulation","volume":"441","author":"Foukas","year":"2006","journal-title":"Nature"},{"key":"10.1093\/annonc\/mdw282_bb0115","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.cell.2006.03.035","article-title":"A pharmacological map of the PI3-K family defines a role for p110\u03b1 in insulin signaling","volume":"125","author":"Knight","year":"2006","journal-title":"Cell"},{"key":"10.1093\/annonc\/mdw282_bb0120","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1634\/theoncologist.2014-0449","article-title":"Phase I dose-escalation study of pilaralisib (SAR245408, XL147), a pan-class I PI3K inhibitor, in combination with erlotinib in patients with solid tumors","volume":"20","author":"Soria","year":"2015","journal-title":"Oncologist"},{"key":"10.1093\/annonc\/mdw282_bb0125","doi-asserted-by":"crossref","first-page":"30392","DOI":"10.1074\/jbc.M103702200","article-title":"Insulin-stimulated activation of eNOS is independent of Ca2+ but requires phosphorylation by Akt at Ser1179","volume":"276","author":"Montagnani","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1093\/annonc\/mdw282_bb0130","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1681\/ASN.2006050541","article-title":"Lack of endothelial nitric oxide synthase promotes endothelin-induced hypertension: lessons from endothelin-1 transgenic\/endothelial nitric oxide synthase knockout mice","volume":"18","author":"Quaschning","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1093\/annonc\/mdw282_bb0135","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1007\/s00109-011-0798-3","article-title":"Regulation of arterial blood pressure by Akt1-dependent vascular relaxation","volume":"89","author":"Ha","year":"2011","journal-title":"J Mol Med (Berl)"},{"key":"10.1093\/annonc\/mdw282_bb0140","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1161\/CIRCRESAHA.108.189316","article-title":"Contribution of insulin and Akt1 signaling to endothelial nitric oxide synthase in the regulation of endothelial function and blood pressure","volume":"104","author":"Symons","year":"2009","journal-title":"Circ Res"},{"key":"10.1093\/annonc\/mdw282_bb0145","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1093\/cvr\/cvq349","article-title":"Insulin says NO to cardiovascular disease","volume":"89","author":"Yu","year":"2011","journal-title":"Cardiovasc Res"},{"key":"10.1093\/annonc\/mdw282_bb0150","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1158\/2159-8290.CD-13-0611","article-title":"Rapid induction of apoptosis by PI3K inhibitors is dependent upon their transient inhibition of RAS-ERK signaling","volume":"4","author":"Will","year":"2014","journal-title":"Cancer Discov"},{"key":"10.1093\/annonc\/mdw282_bb0155","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1158\/1078-0432.CCR-15-2276","article-title":"Strategically timing inhibition of phosphatidylinositol 3-kinase to maximize therapeutic index in estrogen receptor alpha-positive, PIK3CA-mutant breast cancer","volume":"22","author":"Yang","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdw282_bb0160","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1158\/1078-0432.CCR-16-0038","article-title":"Pharmacology in the era of targeted therapies: the case of PI3K inhibitors","volume":"22","author":"Toska","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdw282_bb0165","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1158\/1535-7163.MCT-15-0687","article-title":"Intermittent high-dose scheduling of AZD8835, a novel selective inhibitor of PI3K\u03b1 and PI3K\u03b4, demonstrates treatment strategies for PIK3CA-dependent breast cancers","volume":"15","author":"Hudson","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"10.1093\/annonc\/mdw282_bb0170","first-page":"S5","article-title":"Use of a population pharmacokinetic approach and time-to-event analysis to support the clinical recommendation of a flat dosing of copanlisib in cancer patients","volume":"99","author":"Reif","year":"2016","journal-title":"Clin Pharmacol Ther"},{"key":"10.1093\/annonc\/mdw282_bb0175","doi-asserted-by":"crossref","first-page":"165","DOI":"10.4143\/crt.2014.46.2.165","article-title":"Metabolic burden measured by 18F-Fluorodeoxyglucose positron emission tomography\/computed tomography is a prognostic factor in patients with small cell lung cancer","volume":"46","author":"Kim","year":"2014","journal-title":"Cancer Res Treat"},{"key":"10.1093\/annonc\/mdw282_bb0180","doi-asserted-by":"crossref","first-page":"569","DOI":"10.2967\/jnumed.113.130609","article-title":"Interim 18F-FDG PET SUVmax reduction is superior to visual analysis in predicting outcome early in Hodgkin lymphoma patients","volume":"55","author":"Rossi","year":"2014","journal-title":"J Nucl Med"},{"key":"10.1093\/annonc\/mdw282_bb0185","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/nrc2664","article-title":"Targeting PI3K signalling in cancer: opportunities, challenges and limitations","volume":"9","author":"Engelman","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"10.1093\/annonc\/mdw282_bb0190","first-page":"800","article-title":"Ibrutinib monotherapy in relapsed\/refractory follicular lymphoma (FL): preliminary results of a Phase 2 consortium (P2C) trial","volume":"124","author":"Bartlett","year":"2014","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1093\/annonc\/mdw282_bb0195","doi-asserted-by":"crossref","first-page":"e141","DOI":"10.1038\/bcj.2013.37","article-title":"A novel selective small-molecule PI3K inhibitor is effective against human multiple myeloma in vitro and in vivo","volume":"3","author":"Glauer","year":"2013","journal-title":"Blood Cancer J"},{"key":"10.1093\/annonc\/mdw282_bb0200","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.ctrv.2012.12.012","article-title":"Oral and intravenously administered mTOR inhibitors for metastatic renal cell carcinoma: pharmacokinetic considerations and clinical implications","volume":"39","author":"Danesi","year":"2013","journal-title":"Cancer Treat Rev"},{"key":"10.1093\/annonc\/mdw282_bb0205","doi-asserted-by":"crossref","first-page":"3507","DOI":"10.1158\/1078-0432.CCR-13-2769","article-title":"Targeting PI3K\/mTOR overcomes resistance to HER2-targeted therapy independent of feedback activation of AKT","volume":"20","author":"O'Brien","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdw282_bb0210","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3389\/fonc.2015.00135","article-title":"Inhibitors of pan-PI3K signaling synergize with BRAF or MEK inhibitors to prevent BRAF-mutant melanoma cell growth","volume":"5","author":"Sweetlove","year":"2015","journal-title":"Front Oncol"},{"key":"10.1093\/annonc\/mdw282_bb0215","doi-asserted-by":"crossref","first-page":"11381","DOI":"10.1073\/pnas.0906461107","article-title":"Activity of any class IA PI3K isoform can sustain cell proliferation and survival","volume":"107","author":"Foukas","year":"2010","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419359113?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419359113?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/27\/10\/1928\/19446474\/mdw282.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T07:53:35Z","timestamp":1624694015000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419359113"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":42,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["S0923753419359113"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdw282","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]}}}